Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The accelerated review covers WCK 5222 for multiple critical infections
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Subscribe To Our Newsletter & Stay Updated